Press Release: Elevar Therapeutics : Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium

FORT LEE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced it will present two posters and give an Industry Expert Theater presentation at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).